Year archive

EXACT Therapeutics AS — 2026 filings

All 17 regulatory filings released by EXACT Therapeutics AS (EXTX) in 2026, sourced directly from the official regulator.

17 Filings

2026 Period

2026 filings (17)

Filing	Released	Lang
EXACT Therapeutics - Annual Report 2025 - Attachment: 2025 EXACT Therapeutics AS Annual Report.pdf Annual Report FY 2025	2026-04-09	English
EXACT Therapeutics - Annual Report 2025 Report Publication Announcement	2026-04-09	English
EXACT Therapeutics AS: Share capital increase registered Share Issue/Capital Change	2026-03-26	English
EXACT Therapeutics AS - Minutes from extraordinary general meeting on 13 March 2026 - Attachment: 20260313_EXACT_Therapeutics_-_EGM_minutes.pdf Declaration of Voting Results & Voting Rights Announcements	2026-03-13	Norwegian
EXACT Therapeutics AS - Minutes from extraordinary general meeting on 13 March 2026 Declaration of Voting Results & Voting Rights Announcements	2026-03-13	English
EXACT Therapeutics - First patient dosed in Europe in Phase 2 trial in patients with locally advanced pancreatic cancer Regulatory Filings	2026-03-03	English
EXACT Therapeutics AS: Notice of extraordinary general meeting - Attachment: EGM EXACT Therapeutics AS 27.02.26 (003).pdf Proxy Solicitation & Information Statement	2026-02-27	Norwegian
EXACT Therapeutics AS: Notice of extraordinary general meeting Report Publication Announcement	2026-02-27	English
EXACT Therapeutics AS: Warrants exercise Share Issue/Capital Change	2026-02-27	English
EXACT Therapeutics: Global investor call regarding the ongoing warrants exercise program Call Transcript	2026-02-06	English
EXACT Therapeutics: Correction of final warrants exercise date Regulatory Filings	2026-02-05	English
EXACT Therapeutics: Warrants exercise by leading shareholders and primary insiders - Attachment: 260205 EXACT Therapeutics - company presentation.pdf Investor Presentation	2026-02-05	English
EXACT Therapeutics: Warrants exercise by leading shareholders and primary insiders - Attachment: PDMR attachment - Warrants(22120906.1).pdf Director's Dealing	2026-02-05	English
EXACT Therapeutics: Warrants exercise by leading shareholders and primary insiders Director's Dealing	2026-02-05	English
EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB Capital/Financing Update	2026-02-05	English
EXACT Therapeutics: Positive initial safety read-out from the Phase 2 ENACT trial in pancreatic cancer, triggering option to exercise warrants Regulatory Filings	2026-01-27	English
EXACT Therapeutics’ Phase 2 trial in pancreatic cancer patients to be presented at the 2026 ASCO Gastrointestinal Cancers Symposium Regulatory Filings	2026-01-08	English